Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
CNY 2.31
(2.67%)
CNY 2.31
(2.67%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 570.91 Million CNY | 16.2% |
| 2022 | 395.94 Million CNY | -14.4% |
| 2021 | 462.56 Million CNY | 18.27% |
| 2020 | 391.11 Million CNY | -23.69% |
| 2019 | 512.5 Million CNY | 8.23% |
| 2018 | 473.5 Million CNY | 40.29% |
| 2017 | 337.51 Million CNY | -5.8% |
| 2016 | 358.27 Million CNY | 40.62% |
| 2015 | 254.78 Million CNY | 5.55% |
| 2014 | 241.39 Million CNY | 67.3% |
| 2013 | 144.28 Million CNY | 8.18% |
| 2012 | 133.37 Million CNY | 15.66% |
| 2011 | 115.32 Million CNY | 79.73% |
| 2010 | 64.16 Million CNY | 112.29% |
| 2009 | 30.22 Million CNY | 16.37% |
| 2008 | 25.97 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 105.6 Million CNY | 10.4% |
| 2024 Q1 | 89.76 Million CNY | -61.54% |
| 2024 Q2 | 97.51 Million CNY | 8.63% |
| 2023 Q2 | 137.4 Million CNY | 48.33% |
| 2023 Q1 | 92.63 Million CNY | -26.75% |
| 2023 Q3 | 111.88 Million CNY | -18.57% |
| 2023 Q4 | 233.36 Million CNY | 108.58% |
| 2023 FY | 460.08 Million CNY | 16.2% |
| 2022 Q3 | 85.78 Million CNY | -15.23% |
| 2022 Q1 | 82.51 Million CNY | -42.48% |
| 2022 FY | 395.94 Million CNY | -14.4% |
| 2022 Q4 | 126.45 Million CNY | 47.42% |
| 2022 Q2 | 101.19 Million CNY | 22.64% |
| 2021 FY | 462.56 Million CNY | 18.27% |
| 2021 Q4 | 143.43 Million CNY | 25.82% |
| 2021 Q2 | 115.97 Million CNY | 30.09% |
| 2021 Q3 | 114 Million CNY | -1.69% |
| 2021 Q1 | 89.14 Million CNY | -17.72% |
| 2020 FY | 391.11 Million CNY | -23.69% |
| 2020 Q1 | 83.9 Million CNY | -48.66% |
| 2020 Q2 | 110.21 Million CNY | 31.35% |
| 2020 Q3 | 88.64 Million CNY | -19.57% |
| 2020 Q4 | 108.34 Million CNY | 22.22% |
| 2019 Q3 | 121.24 Million CNY | -3.78% |
| 2019 Q4 | 163.43 Million CNY | 34.8% |
| 2019 Q2 | 126 Million CNY | 23.77% |
| 2019 Q1 | 101.8 Million CNY | -37.08% |
| 2019 FY | 512.5 Million CNY | 8.23% |
| 2018 Q2 | 123.8 Million CNY | 43.86% |
| 2018 Q4 | 161.8 Million CNY | 58.88% |
| 2018 FY | 473.5 Million CNY | 40.29% |
| 2018 Q1 | 86.05 Million CNY | -3.18% |
| 2018 Q3 | 101.84 Million CNY | -17.73% |
| 2017 Q2 | 81.48 Million CNY | 13.2% |
| 2017 FY | 337.51 Million CNY | -5.8% |
| 2017 Q3 | 95.16 Million CNY | 16.79% |
| 2017 Q4 | 88.88 Million CNY | -6.6% |
| 2017 Q1 | 71.97 Million CNY | -44.65% |
| 2016 FY | 358.27 Million CNY | 40.62% |
| 2016 Q3 | 88.05 Million CNY | 14.63% |
| 2016 Q2 | 76.82 Million CNY | 21.26% |
| 2016 Q4 | 130.04 Million CNY | 47.68% |
| 2016 Q1 | 63.34 Million CNY | -17.75% |
| 2015 Q1 | 47.72 Million CNY | -50.5% |
| 2015 Q4 | 77.01 Million CNY | 16.43% |
| 2015 Q3 | 66.14 Million CNY | 3.52% |
| 2015 Q2 | 63.9 Million CNY | 33.9% |
| 2015 FY | 254.78 Million CNY | 5.55% |
| 2014 Q2 | 53.01 Million CNY | 50.76% |
| 2014 Q3 | 56.81 Million CNY | 7.18% |
| 2014 Q4 | 96.4 Million CNY | 69.67% |
| 2014 FY | 241.39 Million CNY | 67.3% |
| 2014 Q1 | 35.16 Million CNY | -16.66% |
| 2013 Q2 | 37.42 Million CNY | 29.31% |
| 2013 Q3 | 35.72 Million CNY | -4.55% |
| 2013 Q4 | 42.19 Million CNY | 18.11% |
| 2013 FY | 144.28 Million CNY | 8.18% |
| 2013 Q1 | 28.94 Million CNY | -38.55% |
| 2012 Q3 | 29.54 Million CNY | 4.1% |
| 2012 Q2 | 28.38 Million CNY | 0.13% |
| 2012 FY | 133.37 Million CNY | 15.66% |
| 2012 Q1 | 28.34 Million CNY | -20.47% |
| 2012 Q4 | 47.09 Million CNY | 59.38% |
| 2011 Q1 | 24.06 Million CNY | -19.1% |
| 2011 Q2 | 26.39 Million CNY | 9.67% |
| 2011 Q4 | 35.64 Million CNY | 21.98% |
| 2011 Q3 | 29.22 Million CNY | 10.72% |
| 2011 FY | 115.32 Million CNY | 79.73% |
| 2010 FY | 64.16 Million CNY | 112.29% |
| 2010 Q4 | 29.74 Million CNY | 65.73% |
| 2010 Q3 | 17.94 Million CNY | 0.0% |
| 2009 FY | 30.22 Million CNY | 16.37% |
| 2008 FY | 25.97 Million CNY | 0.0% |